Nikolaos Markoglou

Natalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directions—a single-center retrospective observational study

Maria Gontika, Charalampos Skarlis, Nikolaos Markoglou et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2022 · 13 citations

Natalizumab Therapy, Autoimmune Disease, Systemic Scleroderma +12

HLA-DPB1*03 as Risk Allele and HLA-DPB1*04 as Protective Allele for Both Early- and Adult-Onset Multiple Sclerosis in a Hellenic Cohort

Maria Anagnostouli, Artemios Artemiadis, Maria Gontika et al. · Brain Sciences · 2020 · 11 citations · Full text

Epidemiologic characteristics of hypertension in the civilians of Kosovo after the war.

Nikolaos Markoglou, Apostolos Hatzitolios, Ch. Savopoulos et al. · PubMed · 2005 · 10 citations

Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data

Maria Gontika, Charalampos Skarlis, Nikolaos Markoglou et al. · Neurological Sciences · 2021 · 10 citations

Second-line Treatment, Adolescent-onset Multiple Sclerosis, Autoimmune Disease +8

First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center

Charalampos Skarlis, Nikolaos Markoglou, Maria Gontika et al. · Neurological Sciences · 2022 · 10 citations · Full text